1. Academic Validation
  2. Design, Synthesis, and Biological Activity of Amine-Type Cyclopentanepyridinone Derivatives as HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors

Design, Synthesis, and Biological Activity of Amine-Type Cyclopentanepyridinone Derivatives as HIV‑1 Non-Nucleoside Reverse Transcriptase Inhibitors

  • ACS Omega. 2025 Jul 18;10(29):32148-32160. doi: 10.1021/acsomega.5c03953.
Nancy Vanessa Castro-Perea 1 Gibran Rodríguez-Vega 2 Julio Cesar Abarca-Magaña 3 Mirna Berenice Ruiz-Rivera 3 José L Medina-Franco 4 Leonor Huerta 3 Daniel Chávez 1
Affiliations

Affiliations

  • 1 National Technological of Mexico/Tijuana Technological Institute, Center for Graduate and Research in Chemistry, Postal Box 1166, Tijuana, Baja California 22000, Mexico.
  • 2 Academic Unit of Chemical Biological and Pharmaceutical Sciences, Autonomous University of Nayarit, Tepic, Nayarit 63000, Mexico.
  • 3 Biomedical Research Institute, Department of Immunology, National Autonomous University of Mexico, Mexico City 04510, Mexico.
  • 4 DIFACQUIM Research group, Department of Pharmacy, School of Chemistry, National Autonomous University of Mexico, Mexico City 04510, Mexico.
Abstract

Non-nucleoside Reverse Transcriptase inhibitors (NNRTIs) targeting human immunodeficiency virus (HIV) frequently exhibit suboptimal pharmacological properties and are often compromised by drug-resistant mutations. This underscores the ongoing need for the development of developing novel Reverse Transcriptase (RT) inhibitors. In this study, we report the synthesis of 20 novel amine-type cyclopentanepyridinone derivatives as NNRTIs. The chlorinated C-4 core was functionalized with various amines of differing chain lengths, yielding final products in 43-88% yields. Derivatives bearing alkyl and alkenyl chains at the C-4 position demonstrated anti-HIV activity at nanomolar to micromolar concentrations. Among them, compound 9 exhibited the most potent inhibitory activity against HIV and wild-type (WT) HIV-1 RT, with an EC50 of 540 nM and an IC50 of 33.89 μM, respectively, while maintaining low cytotoxicity (CC50 > 100 μM). Molecular docking analysis revealed interactions with key residues in the NNRTI binding pocket (NNIBP), including Lys101, Tyr181, Tyr188, and the conserved residues Phe227, Trp229, and Leu234, both in WT HIV-1 RT and Tyr188Leu HIV-1 RT. Moreover, molecular dynamics (MD) simulations with WT HIV-1 RT showed that compounds 6, 9, and 10 formed up to two hydrogen bonds with RT, supporting their ability to bind effectively within the NNIBP.

Figures
Products